PSORIATIC ARTHRITIS: AN ALGORITHM FOR MAKING A DECISION ON THE CHOICE OF MANAGEMENT TACTICS

Psoriatic arthritis (PA) is a chronic inflammatory disease of the joints, vertebral column, and entheses from a group of seronegative spondyloarthritides, which is observed in patients with psoriasis. In accordance with the 2013 federal clinical guidelines for the management of patients with PA, published by the Russian Society of Dermatovenereologists and Cosmetologists and the Association of Rheumatologists of Russia, its diagnosis should be based on the CASPAR criteria (ClASsification criteria for Psoriatic ARthritis, 2006). The activity of spondylitis in PA is assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) that is a questionnaire containing 6 questions; a numeric rating scale from 0 (“very good”) to 10 (“very bad”) scores is applied for a response. It is recommended that ultrasound studies and magnetic resonance tomography be used for the early diagnosis of enthesitis in seronegative spondyloarthritides. The Psoriasis Area Severity Index (PASI) that takes into account the area of the lesion, the magnitude of erythema, infiltration, and desquamation in different body areas. The early diagnosis of PA and the timely use of disease-modifying antirheumatic therapy are topical problems, as high-activity inflammation may lead to rapid joint destruction, physical limitations, and disability. When the signs of active PA (the presence of one or more swollen and tender joints, and/or 1 or more dactylitides, and/or more enthesitides and/or inflammatory back pain) are detected, prompt drug therapy is indicated. The clear compliance of the algorithm for making a decision on treatment policy and the timely assessment of the clinical manifestations of the disease improves prognosis, adherence to treatment, and quality of life.

seronegative spondyloarthritis, psoriasis, psoriatic arthritis, dactylitis, enthesitis, spondylitis, diagnostic criteria for psoriatic arthritis, inflammatory back pain, treatment of psoriatic arthritis, methotrexate

1. Российское общество дерматовенерологов и косметологов. Федеральные клинические рекомендации по ведению больных псориазом. М., 2015. Доступно по ссылке: http://www.cnikvi.ru/docs/clinic_recs/bolezni-kozhi-i-pridatkov-kozhi/. [Russian Dermatovenerologists’ and Cosmetologists’ Society. Federal clinical recommendations for the treatment of patients with psoriasis. Мoscow, 2015. Available at: http://www.cnikvi.ru/docs/ clinic_recs/bolezni-kozhi-i-pridatkovkozhi/.(In Russ.)].

2. Reich K., Krüger K., Mössner R., Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaquetype psoriasis. Br J Dermatol 2009; 160(5):1040–7.

3. Gladman D.D., Antoni C., Mease P.J. et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14–7.

4. Moll J.M., Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973;32(3):181–201.

5. Dougados M., van der Linden S., Juhlin R. et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991;34(10):1218–27.

6. Бадокин В.В. Клиника и диагностика псориатического артрита. М., 2004. [Badokin V.V. Clinics and diagnostics of the psoriatic arthritis. Мoscow, 2004. (In Russ.)].

7. Агабабова Э.Р., Бадокин В.В., Эрдес Ш. и др. Разработка и апробация диагностических критериев псориатического артрита. Терапевтический архив 1989;61(12):117–21. [Аgababovа E.R., Badokin V.V., Erdes Sh. et. al. Development and approbation of diagnostic criteria of the psoriatic arthritis. Terapevticheskiy arkhiv = Тherapeutic Archive 1989;61(12):117–21. (In Russ.)].

8. Бадокин В.В. К вопросу о классификации псориатического артрита. Клиническая ревматология 1995;(1):53–6. [Badokin V.V. To the issue on the classification of psoriatic arthritis. Klinicheskaya revmatologiya = Clinical Rheumatology 1995;(1):53–6. (In Russ.)].

9. Российское общество дерматовенерологов и косметологов, Ассоциация ревматологов России. Федеральные клинические рекомендации по ведению больных псориатическим артритом. М., 2013. Доступно по ссылке: http://rheumatolog.ru/experts/

10. klinicheskie-rekomendacii. Russian Dermatovenerologists’ and Cosmetologists’ Society, Аssociation of Rheumatologists of Russia. Federal clinical recommendations for patients with psoriatic arthritis. Мoscow, 2013. Available at: http://rheumatolog.ru/experts/klinicheskie-rekomendacii. (In Russ.)].

11. Sieper J., van der Heijde D., Landewé R. et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis 2009;68(6):784–8.

12. Taylor W.J., Gladman D.D., Helliwell P.S. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54(8):2665–73.

13. Heulf-Dorenbosch L., Spoorrenberg A., van Tubergen A. et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62(2):127–32.

14. PASI score. Available at: http://www.dermnetnz.org/scaly/pasi.html.

15. Gladman D.D. Psoriatic arthritis. Dermatol Ther 2009;22(1):40–55.

16. Gladman D.D., Thavaneswaran A., Chandran V. et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis 2011;70(12):2152–4.

17. Gossec L., Smolen J.S., Gaujoux-Viala C. et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71(1):4–12.

18. Gossec L., Smolen J.S., Ramiro S.et al. European League Against Rheumatism

19. (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2015;74:1327–39.

20. Wong K., Gladman D.D., Husted J. et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40(10):1868–72.

21. Gladman D.D., Farewell V.T., Wong K. et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41(6):1103–10.

22. Chin Y.Y., Yu H.S., Li W.C. et al. Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. J Eur Acad Dermatol Venereol 2013;27(10):1262–8.

23. Шостак Н.А., Клименко А.А. Современные подходы к диагностике и лечению псориатического артрита (обзор). Терапевтический архив 2008;80(10):82–7. [Shostak N.А., Klimenko А.А. Modern approaches to the diagnostics and treatment of the psoriatic arthritis (review). Terapevticheskiy arkhiv = Тherapeutic Archive 2008;80(10):82–7. (In Russ.)].